delavirdine + zidovudine + indinavir + lamivudine

This is a **four-drug antiretroviral combination** consisting of **delavirdine**, **zidovudine**, **indinavir**, and **lamivudine**, each with a distinct mechanism targeting HIV-1 replication. - **Delavirdine** is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, inhibiting HIV-1 replication. - **Zidovudine** (AZT) and **lamivudine** (3TC) are nucleoside reverse transcriptase inhibitors (NRTIs) that block reverse transcriptase activity by acting as chain terminators during DNA synthesis. - **Indinavir** is a protease inhibitor, preventing maturation of infectious HIV particles by inhibiting the viral protease. This specific four-drug combination has been studied in the context of HIV-1 infection, particularly after virologic failure or in heavily pretreated patients. Clinical data indicate that adding **delavirdine** to the triple combination of **zidovudine + indinavir + lamivudine** resulted in further viral suppression and improved immunologic parameters in some patients[3]. Resistance and side effects, such as rash (delavirdine), anemia/neutropenia (zidovudine), kidney stones (indinavir), and gastrointestinal disturbances, should be carefully monitored.